Sionna Therapeutics (NASDAQ:SION) Upgraded by Wedbush to Strong-Buy Rating

Wedbush upgraded shares of Sionna Therapeutics (NASDAQ:SION) to a strong-buy rating in a research report sent to investors on Monday,Zacks.com reports.

Other equities research analysts also recently issued research reports about the stock. Raymond James Financial restated a “strong-buy” rating and issued a $53.00 price target on shares of Sionna Therapeutics in a research report on Monday, January 5th. UBS Group restated a “buy” rating on shares of Sionna Therapeutics in a research report on Monday, March 2nd. BTIG Research restated a “buy” rating and issued a $58.00 price target on shares of Sionna Therapeutics in a research report on Monday, April 27th. JonesTrading upped their price target on shares of Sionna Therapeutics from $52.00 to $63.00 and gave the company a “buy” rating in a research report on Tuesday, April 28th. Finally, Guggenheim upped their price target on shares of Sionna Therapeutics from $45.00 to $50.00 and gave the company a “buy” rating in a research report on Monday, March 2nd. Three equities research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $53.00.

Sionna Therapeutics Stock Performance

Shares of NASDAQ:SION opened at $40.97 on Monday. The company has a market cap of $1.85 billion, a PE ratio of -21.01 and a beta of 1.35. Sionna Therapeutics has a 52 week low of $11.77 and a 52 week high of $46.46. The firm has a 50 day simple moving average of $38.29 and a 200 day simple moving average of $39.20.

Sionna Therapeutics (NASDAQ:SION) last issued its quarterly earnings results on Monday, March 2nd. The company reported ($0.46) EPS for the quarter, beating the consensus estimate of ($0.61) by $0.15. On average, equities analysts predict that Sionna Therapeutics will post -2.44 earnings per share for the current year.

Insider Buying and Selling

In other Sionna Therapeutics news, Director Peter A. Thompson sold 2,948 shares of the stock in a transaction that occurred on Saturday, April 18th. The shares were sold at an average price of $44.52, for a total value of $131,244.96. Following the completion of the sale, the director owned 2,964,774 shares in the company, valued at $131,991,738.48. This represents a 0.10% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Orbimed Advisors Llc sold 2,948 shares of the stock in a transaction that occurred on Saturday, April 18th. The stock was sold at an average price of $44.52, for a total transaction of $131,244.96. Following the completion of the sale, the director owned 2,964,774 shares of the company’s stock, valued at approximately $131,991,738.48. The trade was a 0.10% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 1,131,856 shares of company stock valued at $50,834,773. Insiders own 3.90% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. GF Fund Management CO. LTD. bought a new position in shares of Sionna Therapeutics during the 4th quarter valued at $36,000. Russell Investments Group Ltd. bought a new position in shares of Sionna Therapeutics during the 3rd quarter valued at $30,000. Balyasny Asset Management L.P. bought a new position in shares of Sionna Therapeutics during the 4th quarter valued at $58,000. BNP Paribas Financial Markets bought a new position in shares of Sionna Therapeutics during the 2nd quarter valued at $31,000. Finally, Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Sionna Therapeutics during the 4th quarter valued at $89,000.

Sionna Therapeutics Company Profile

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.